• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, October 30, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Four Physiological Phenotypes May Guide Intensive Care in Autoimmune Lung Disease Flare-Ups

by
October 29, 2026
in Health
Reading Time: 2 mins read
0
Four Physiological Phenotypes May Guide Intensive Care in Autoimmune Lung Disease Flare-Ups

Four Physiological Phenotypes May Guide Intensive Care in Autoimmune Lung Disease Flare-Ups

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In some of these patients the lung disease suddenly worsens, causing acute respiratory failure that frequently requires intensive care. A new Perspective article published in Critical Care argues that these acute exacerbations, abbreviated AE-SARD-ILD, are too often treated with templates borrowed from other conditions, and proposes a new framework built around four physiological phenotypes instead.

They argue that this approach overlooks the heterogeneity of the underlying pathological processes. According to the article, AE-SARD-ILD encompasses distinct patterns of respiratory mechanics, pulmonary vascular involvement, reversibility and treatment response, so management based solely on the underlying rheumatic disease or on the radiological pattern may be inadequate.

Instead of classifying patients only by their rheumatic diagnosis or imaging-based fibrotic pattern, the proposed integrated clinical, radiological and mechanical framework identifies four dominant, potentially overlapping physiological phenotypes. These arise from the interaction between the chronic pulmonary substrate and the superimposed acute insult: a fibrotic or UIP-like phenotype, an inflammatory or ARDS-like phenotype, a pulmonary hypertension-dominant phenotype, and a diffuse alveolar haemorrhage-dominant phenotype. The authors emphasize that these categories are not mutually exclusive and may overlap in individual patients.

The practical purpose of the framework is to give clinicians a physiological rationale for selecting, titrating and escalating respiratory support, both non-invasive and invasive. The phenotypes are also intended to guide control of excessive respiratory drive and the integration of immunomodulatory therapies, pulmonary vascular treatments and extracorporeal support strategies. Because the four phenotypes differ in reversibility and expected treatment response, the authors suggest they could support individualized respiratory management, dynamic prognostication and time-limited trials of intensive care, in which the benefit of continued critical support is periodically reassessed.

Important limitations accompany the proposal. The article is a Perspective, a review and position piece rather than a study reporting new patient data, and its recommendations rest on a synthesis of current evidence rather than on prospective testing of the framework itself. The authors state explicitly that prospective validation is required before phenotype-based assessment can be considered an established standard of care. Readers should therefore treat the four-phenotype model as a structured proposal for future research and clinical reasoning, not as a validated treatment algorithm. Even so, the article offers a concrete way of thinking about a rare but severe complication: instead of asking only which rheumatic disease a patient has or how their chest imaging looks, clinicians could ask which physiological process is dominating the acute deterioration, and tailor respiratory support and drug therapy to that process.

Subject of Research: Physiological phenotypes guiding respiratory and intensive care management of acute exacerbation of autoimmune rheumatic disease-associated interstitial lung disease

Article Title: Acute exacerbation of systemic autoimmune rheumatic disease-associated interstitial lung disease: integrated pathophysiology and respiratory care

Article References: Tonelli, R., Orlandi, M., Cuculo, A., Lodeserto, A., Michelacci, S., Keller Sarmiento, L., Moretti, A., Samarelli, A. V., Raineri, G., Cerri, S., Giuggioli, D., Marchioni, A., & Clini, E. (2026). Acute exacerbation of systemic autoimmune rheumatic disease-associated interstitial lung disease: integrated pathophysiology and respiratory care. Critical Care. https://doi.org/10.1186/s13054-026-06395-x

Image Credits: AI Generated

DOI: 10.1186/s13054-026-06395-x

Keywords: interstitial lung disease, autoimmune rheumatic disease, acute exacerbation, acute respiratory failure, intensive care, physiological phenotypes, pulmonary hypertension, diffuse alveolar haemorrhage, ARDS, non-invasive ventilation, respiratory mechanics, perspective article

News Source: Barbara Leach. (October 29, 2026). Four Physiological Phenotypes May Guide Intensive Care in Autoimmune Lung Disease Flare-Ups. Scienmag.

Tags: acute exacerbationacute respiratory failureARDSautoimmune rheumatic diseasediffuse alveolar haemorrhageintensive careinterstitial lung diseasenon-invasive ventilationperspective articlephysiological phenotypespulmonary hypertensionrespiratory mechanics
Share12Tweet7Share2ShareShareShare1

Related Posts

ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth

ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth

October 30, 2026
Most Ethiopian HIV patients on dolutegravir therapy show good knowledge, survey finds

Most Ethiopian HIV patients on dolutegravir therapy show good knowledge, survey finds

October 30, 2026

Serum and urine protein biomarkers may sharpen prostate cancer detection beyond PSA

October 30, 2026

One gene locus flags atrial fibrillation risk after major surgery, UK Biobank study finds

October 30, 2026

POPULAR NEWS

  • Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant

    Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant

    29 shares
    Share 12 Tweet 7
  • Firebreaks Leave Lasting Scars in Grasslands While Wildfire Heals Fast

    29 shares
    Share 12 Tweet 7
  • ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth

    29 shares
    Share 12 Tweet 7
  • Systematic review maps sustainability tensions in offshore wind development

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant

Firebreaks Leave Lasting Scars in Grasslands While Wildfire Heals Fast

ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 86 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.